- Home
- LODE vs ACRS Comparison
LODE vs ACRS Comparison
Compare LODE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LODE
- ACRS
- Stock Information
- Founded
- LODE 2008
- ACRS 2012
- Country
- LODE United States
- ACRS United States
- Employees
- LODE N/A
- ACRS N/A
- Industry
- LODE Major Chemicals
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- LODE Industrials
- ACRS Health Care
- Exchange
- LODE Nasdaq
- ACRS Nasdaq
- Market Cap
- LODE 168.0M
- ACRS 198.2M
- IPO Year
- LODE N/A
- ACRS 2015
- Fundamental
- Price
- LODE $2.75
- ACRS $2.34
- Analyst Decision
- LODE Hold
- ACRS Strong Buy
- Analyst Count
- LODE 1
- ACRS 9
- Target Price
- LODE $4.00
- ACRS $9.25
- AVG Volume (30 Days)
- LODE 1.5M
- ACRS 1.6M
- Earning Date
- LODE 10-30-2025
- ACRS 11-06-2025
- Dividend Yield
- LODE N/A
- ACRS N/A
- EPS Growth
- LODE N/A
- ACRS N/A
- EPS
- LODE N/A
- ACRS N/A
- Revenue
- LODE $2,778,445.00
- ACRS $15,742,000.00
- Revenue This Year
- LODE $7.65
- ACRS N/A
- Revenue Next Year
- LODE $1,093.72
- ACRS N/A
- P/E Ratio
- LODE N/A
- ACRS N/A
- Revenue Growth
- LODE 48.99
- ACRS N/A
- 52 Week Low
- LODE $1.67
- ACRS $1.05
- 52 Week High
- LODE $10.10
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- LODE 37.63
- ACRS 56.23
- Support Level
- LODE $2.71
- ACRS $2.13
- Resistance Level
- LODE $3.48
- ACRS $2.64
- Average True Range (ATR)
- LODE 0.24
- ACRS 0.25
- MACD
- LODE -0.07
- ACRS -0.01
- Stochastic Oscillator
- LODE 12.50
- ACRS 45.52
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.